liraglutide 3 mg / Generic mfg. - LARVOL DELTA

Pharmacotherapy for obesity management. (PubMed, S Afr Med J) - "Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications, in conjunction with medical nutrition therapy, physical activity and psychological interventions (semaglutide 2.4 mg weekly [Level 1a, Grade A] liraglutide 3.0 mg daily [Level 2a, grade B], naltrexone/bupropion 16 mg/180 mg twice a day [BID] [Level 2a, Grade B], orlistat 120 mg three times a day [TID] [Level 2a, Grade B])...Metformin and psychological treatment (such as cognitive behavioural therapy) should be considered for prevention of weight gain in people with severe mental illness who are treated with antipsychotic medications associated with weight gain (Level 1a, Grade A)...9. We do not suggest the use of prescription or over-the-counter medications other than those approved in SA for obesity management (Level 4, Grade D, Consensus)."

Journal • CNS Disorders • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

Regulator releases new safety warnings for weight loss and diabetes drugs including Ozempic, Wegovy and Mounjaro (News.com.au) - "The safety alert issued by the regulator on Monday details links to two separate safety issues; the potential risk of suicidal thoughts, and reduced effectiveness of oral contraception...It relates to GLP-1 and dual GIP/GLP-1 receptor agonists which are primarily prescribed to manage type 2 diabetes and obesity, and are marketed in Australia as Ozempic (semaglutide) Wegovy (semaglutide), Saxenda (liraglutide), Trulicity (dulaglutide) and Mounjaro (tirzepatide)."

Non-US regulatory • Obesity • Type 2 Diabetes Mellitus

WHO releases its first guidelines on GLP-1s (The Hill) - "The WHO’s guidelines stated GLP-1s may be used for the long-term treatment of obesity in adults, excluding pregnant women. This recommendation is 'conditional' as there is currently 'limited data on their long-term efficacy and safety'....The guidelines specifically applied to three GLP-1 medications: liraglutide, semaglutide and tirzepatide. Semaglutide and tirzepatide are perhaps the most well-known GLP-1s in the U.S., sold commercially as Wegovy and Zepbound respectively when prescribed for weight management. Liraglutide is sold commercially as Saxenda in the U.S."

Clinical guideline • Obesity

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review. (PubMed, J Obes) - "GLP-1 RAs, especially semaglutide and tirzepatide, are effective for weight management. Liraglutide may remain a viable, cost-effective alternative."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece. (PubMed, Front Public Health) - "Deterministic and scenario analysis identified treatment duration, time horizon, discount rates, and diabetes-related complication costs as key drivers of ICER variability. Semaglutide 2.4 mg is likely to be a cost-effective treatment option compared to liraglutide 3 mg for patients with a BMI ≥ 35 and at least one weight-related comorbidity in Greece."

HEOR • Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System (ISPOR-EU 2025) - "Liraglutide (Saxenda®) is the only GLP-1 RA currently reimbursed for weight management (under a health technology management approach with individual reimbursement applications required) since January 2023...Data for GLP-1 RA usage (liraglutide, semaglutide, dulaglutide, exenatide) was combined across the LTI/DP/GMS schemes... The number of individuals in receipt of a GLP-1 RA in Ireland has increased by 142% between January 2022 and December 2024. Comparing total monthly expenditure in January 2022 and December 2024, there has been an increase in expenditure of 129.5%. Total annual expenditure has increased by 71.5% between 2022 and 2024."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Real-World Outcomes of GLP-1 Therapy in a Multidisciplinary Obesity Center in Colombia (OBESITY WEEK 2025) - " A retrospective analysis assessed outcomes of patients prescribed liraglutide (Saxenda®) at Fundación Santa Fe de Bogotá Obesity Center between 2021 and 2024, indicated exclusively for non-surgical management following multidisciplinary clinical review... In a real-world Latin American setting, a structured multidisciplinary program incorporating GLP-1 receptor agonists achieved greater weight loss and improvements in body composition than those typically reported in the SCALE trials and other real-world studies. These results highlight the enhanced effectiveness of combining pharmacologic therapy with intensive lifestyle and behavioral interventions in clinical obesity management."

Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Genetic Disorders • Hepatology • Hypertension • Metabolic Disorders • Mood Disorders • Obesity • Psychiatry • Type 2 Diabetes Mellitus

Primary Non-Adherence with GLP-1 and GIP Medications for Obesity Management (OBESITY WEEK 2025) - " Using Optum's Market Clarity database, patients with a written prescription (WRx) for Saxenda (liraglutide), Wegovy (semaglutide), or Zepbound (tirzepatide) from January 2024 through September 2024 were identified. Less than half of patients prescribed an OMM of interest filled their prescription within 45 days, suggesting patients may need additional support initiating OMMs. Primary adherence estimates may be impacted by insurance coverage, out of pocket costs, or drug shortages. Reasons for primary non-adherence should be investigated to identify barriers to treatment initiation and to inform the design of programs to improve patient adherence."

Adherence • Genetic Disorders • Obesity

GLP-1 Agonist Medications Decrease Sexual Desire: A Biopsychosocial Model for Why We Don't 'See' It (OBESITY WEEK 2025) - "Background: While prevailing assumptions suggest that improved body image and erectile function, even in people with diabetes, associated with GLP-1 agonists (semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), dulaglutide (Trulicity), exenatide (Byetta), lixisenatide (Adlyxin)) would correlate with heightened sexual desire and function, there is limited literature on the underlying biological effects of GLP-1 agonists on hedonistic pleasures such as sex. Failing to systematically measure and report on sexual desire and downstream function as a potential adverse outcome of GLP-1 agonist use neglects an essential aspect of patient well-being. Analyzing the unique interplay of the biopsychosocial implications of GLP-1 agonists is novel and important. We recognize that our theoretical model is rooted in a chain of substantiated assumptions."

Biopsy • Diabetes • Metabolic Disorders

Effects of Liraglutide on Energy Intake in Adolescents With Obesity Post-Vertical Sleeve Gastrectomy (OBESITY WEEK 2025) - "Liraglutide 3.0 mg/d for 16 weeks significantly reduced total food mass and energy intake without changing macronutrient distribution in adolescents who had obesity ≥1 year following sleeve gastrectomy. Decreases in fiber, sugar, sodium, and saturated and monounsaturated fats may indicate that overall food intake decreased without substantially altering the types of foods chosen. In this study of adolescents with normal baseline glucose tolerance, liraglutide did not improve glucose or insulin AUC during OGTT."

Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity

Major announcement on availability of weight-loss drugs on NHS in Wales (WalesOnline) - "GPs will continue to be blocked from prescribing new weight-loss drugs by the Welsh Government because NHS Wales is not ready for the huge demand....An exception exists for a small number of high-need patients who, for example, have cancer, need a transplant, or are in the care of fertility services....The specialist-only rule also applies to semaglutide (Wegovy) and liraglutide (Saxenda), two other weight-loss drugs, with a global surge in demand far outstripping supply."

Reimbursement • Obesity

Liraglutide as a treatment option for weight regain after laparoscopic sleeve gastrectomy in patients with obesity and higher anaesthesiologist risk. (PubMed, Front Surg) - "At the conclusion of the 6-month, all patients achieved a median weight of 75 kg and a BMI of 28.7 kg/m2, demonstrating a significant decline from the 3-month measurements, with a %TWL of 27.5%. Liraglutide, at a maximum dosage of 3.0 mg, has the potential to mitigate weight regain after LSG in patients who are not appropriate candidates for revisional surgery due to various comorbidities."

Journal • Anesthesia • Gastrointestinal Disorder • Genetic Disorders • Obesity

Semaglutide (Wegovy) for MASH. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Exposure to High-Dose Liraglutide in a Pregnant Woman With Obesity. (PubMed, O G Open) - "This case report demonstrates a normal pregnancy outcome after exposure to a high dose of liraglutide during the first 7 weeks of pregnancy, apart from a low birth weight. These findings enhance the limited understanding of liraglutide exposure during pregnancy. More studies are required to establish a causal relationship between neonatal weight and liraglutide exposure. Longitudinal follow-up of children beyond 14 months is essential to evaluate growth and neurodevelopmental outcomes and assess any long-term teratogenic effects from anti-obesity drugs."

Journal • Diabetes • Genetic Disorders • Gestational Diabetes • Metabolic Disorders • Obesity

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy (clinicaltrials.gov) - P4 | N=60 | Suspended | Sponsor: The Cleveland Clinic | Phase classification: P=N/A ➔ P4 | N=120 ➔ 60 | Recruiting ➔ Suspended

Enrollment change • Phase classification • Trial suspension • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Louisiana State University Health Sciences Center in New Orleans | Trial completion date: Jul 2025 ➔ Feb 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Inflammation • Obesity

Weight loss maintenance with exercise but not with GLP-1 receptor agonist treatment decreases atherosclerosis development (EASD 2025) - P4 | "Of 215 total participants, 195 participants completed an 8-week low-calorie diet (see Table 1 for baseline characteristics) and were randomly assigned to 52 weeks of weight loss maintenance with or without exercise and glucagon-like peptide-1 receptor agonist liraglutide 3.0 mg/day or placebo treatment. Exercise, but not incretin-based therapy, decreased atherosclerosis development during weight loss maintenance. Since both exercise and incretin-based treatment maintained weight loss, this suggests that exercise plays a key role in mitigating cardiovascular risk factors in a weight-independent manner."

Clinical • Diabetes • Metabolic Disorders • Obesity • ICAM1 • IFNG • IL6 • VCAM1

Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity. (PubMed, Osteoporos Int) - "Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO)...The impact of glucagon-like peptide-1 receptor agonists (GLP-1Ra) on bone health remains unclear. Although preliminary findings indicate that GLP-1Ra causes modest bone mineral density reduction and enhances bone remodeling, favoring resorption similar to the effects of calorie restriction, further research is needed on fracture-related outcomes in people living with obesity."

Journal • Review • Genetic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics • Osteoporosis

Saxenda: Patents delisted from Orange Book (Orange Book) - Patent no.s 10220155, 10220155*PED, 10357616, 10376652, 11097063, 11311679, 11446443, 8684969, 8684969*PED, 8920383, 8920383*PED, 9108002, 9108002*PED, 9132239, 9132239*PED, 9457154, 9457154*PED, 9616180, 9616180*PED, 9687611, 9687611*PED, 9775953, 9775953*PED, 9861757, 9861757*PED, RE46363, RE46363*PED

Patent • Obesity

Novo Nordisk weight-loss injections Saxenda and Wegovy…have been prescribed more than 1.1 million times in Korea over the past five years, according to newly released data. (Korea Biomedical Review) - "Between January 2020 and June 2025, the Drug Utilization Review (DUR) system recorded 721,310 prescriptions for Saxenda and 395,384 for Wegovy, totaling 1,116,694 cases....Regionally, demand was concentrated in metropolitan areas, with 40.2 percent of prescriptions in Seoul and 23.5 percent in Gyeonggi Province."

Commercial • Obesity

Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss (Teva Press Release)

FDA approval • Generic launch • Obesity

Saxenda: “Extension of indication to include the use of SAXENDA for weight management in children from the age of 6 years to less than 12 years based on results from study NN8022- 4392…as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 34.0 of the RMP has also been submitted.” (European Medicines Agency) - CHMP Final Minutes of the meeting on 24 - 27 Feb 2025: “The committee adopted a 2nd request for supplementary information with a specific timetable”

CHMP • Obesity

Saxenda: “Extension of indication to include the use of SAXENDA for weight management in children from the age of 6 years to less than 12 years based on results from study NN8022- 4392…as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 34.0 of the RMP has also been submitted.” (European Medicines Agency) - CHMP Final Minutes of the meeting on 19 - 22 May 2025: “The committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable”

CHMP • Obesity

Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. (PubMed, Adv Ther) - "On the basis of this simulation model, at the UK willingness-to-pay threshold (£20,000/QALY gained), tirzepatide is a cost-effective treatment compared to liraglutide for overweight and obesity, in both the full license SURMOUNT-1 trial population and in liraglutide's specific NICE reimbursed population."

HEOR • Journal • Cardiovascular • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics

Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review. (PubMed, Diabetes Metab Syndr Obes) - "Tirzepatide, a dual GLP-1/GIP agonist, shows promise for weight loss, but its safety compared to GLP-1 receptor agonists requires (liraglutide, semaglutide) clarification for clinical decision-making. Liraglutide 3.0 mg was associated with higher overall adverse events, while tirzepatide (10 or 15 mg) showed increased severe hypoglycemia and injection-site reactions risk but superior anti-inflammatory and anti-neoplasm effects compared to GLP-1 mono-agonists. These findings highlight therapy-specific safety patterns critical for personalized treatment selection."

Journal • Review • Dyspepsia • Genetic Disorders • Infectious Disease • Obesity • Oncology • Pain • Respiratory Diseases • Severe Hypoglycemia • Type 2 Diabetes Mellitus